Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS.

J Clin Oncol. 2011 Dec 1;29(34):4482-90. doi: 10.1200/JCO.2010.33.8715. Epub 2011 Oct 24.

2.

Molecular subtypes of glioblastoma are relevant to lower grade glioma.

Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS.

PLoS One. 2014 Mar 10;9(3):e91216. doi: 10.1371/journal.pone.0091216. eCollection 2014.

3.

Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.

Agnihotri S, Aldape KD, Zadeh G.

Neurosurg Focus. 2014 Dec;37(6):E13. doi: 10.3171/2014.9.FOCUS14505. Review.

PMID:
25434382
4.

DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.

Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H.

Acta Neuropathol Commun. 2015 Jun 20;3:34. doi: 10.1186/s40478-015-0213-3.

5.

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G.

Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0. Epub 2015 Mar 18.

6.

A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.

Chen C, Shi Y, Li Y, He ZC, Zhou K, Zhang XN, Yang KD, Wu JR, Kung HF, Ping YF, Bian XW.

J Genet Genomics. 2017 Nov 20;44(11):519-530. doi: 10.1016/j.jgg.2017.05.007. Epub 2017 Sep 21.

PMID:
29169920
7.

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, de Reyniès A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F.

Neuro Oncol. 2011 Jan;13(1):84-98. doi: 10.1093/neuonc/noq110. Epub 2010 Oct 5.

8.

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.

Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A.

Hum Mutat. 2009 Jan;30(1):7-11. doi: 10.1002/humu.20937.

PMID:
19117336
9.

IDH1 mutation of gliomas with long-term survival analysis.

Myung JK, Cho HJ, Park CK, Kim SK, Phi JH, Park SH.

Oncol Rep. 2012 Nov;28(5):1639-44. doi: 10.3892/or.2012.1994. Epub 2012 Aug 24.

PMID:
22922798
10.

Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.

Sipayya V, Sharma I, Sharma KC, Singh A.

J Cancer Res Ther. 2012 Oct-Dec;8(4):598-601. doi: 10.4103/0973-1482.106567.

PMID:
23361281
11.

Cystic glioblastoma: an evaluation of IDH1 status and prognosis.

Sarmiento JM, Nuño M, Ortega A, Mukherjee D, Fan X, Black KL, Patil CG.

Neurosurgery. 2014 Jan;74(1):71-5: discussion 75-6. doi: 10.1227/NEU.0000000000000200.

PMID:
24089051
12.

Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults.

Jha P, Suri V, Singh G, Jha P, Purkait S, Pathak P, Sharma V, Sharma MC, Suri A, Gupta D, Mahapatra AK, Sarkar C.

Diagn Mol Pathol. 2011 Dec;20(4):225-32. doi: 10.1097/PDM.0b013e31821c30bc.

PMID:
22089350
13.

Genetic characterization of gliomas arising in patients with multiple sclerosis.

Khalil A, Serracino H, Damek DM, Ney D, Lillehei KO, Kleinschmidt-DeMasters BK.

J Neurooncol. 2012 Sep;109(2):261-72. doi: 10.1007/s11060-012-0888-2. Epub 2012 May 1.

PMID:
22547311
14.

IDH2 mutation in gliomas including novel mutation.

Koh J, Cho H, Kim H, Kim SI, Yun S, Park CK, Lee SH, Choi SH, Park SH.

Neuropathology. 2015 Jun;35(3):236-44. doi: 10.1111/neup.12187. Epub 2014 Dec 12.

PMID:
25495392
15.

Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R132H mutation-negative glioblastoma.

Kondo N, Barth RF, Miyatake SI, Kawabata S, Suzuki M, Ono K, Lehman NL.

J Neurooncol. 2017 May;133(1):107-118. doi: 10.1007/s11060-017-2408-x. Epub 2017 May 22.

16.

Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.

Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Kayama T, Shibui S.

Brain Tumor Pathol. 2012 Oct;29(4):183-91. doi: 10.1007/s10014-012-0113-1. Epub 2012 Jul 13.

PMID:
22790483
17.

Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.

Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM.

Neuro Oncol. 2014 Mar;16(3):414-20. doi: 10.1093/neuonc/not198. Epub 2013 Dec 4.

18.

Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.

Wang XW, Boisselier B, Rossetto M, Marie Y, Idbaih A, Mokhtari K, Gousias K, Hoang-Xuan K, Delattre JY, Simon M, Labussière M, Sanson M.

Cancer. 2013 Feb 15;119(4):806-13. doi: 10.1002/cncr.27798. Epub 2012 Nov 26.

19.

Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.

Kawasoe T, Takeshima H, Yamashita S, Mizuguchi S, Fukushima T, Yokogami K, Yamasaki K.

J Neurosurg. 2015 Feb;122(2):317-23. doi: 10.3171/2014.10.JNS132159. Epub 2014 Nov 21.

PMID:
25415071
20.

Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.

Doll S, Urisman A, Oses-Prieto JA, Arnott D, Burlingame AL.

Mol Cell Proteomics. 2017 Jan;16(1):39-56. doi: 10.1074/mcp.M116.063883. Epub 2016 Nov 10.

Supplemental Content

Support Center